AC Immune SA
corporate_fare Company Profile
AC Immune SA (NASDAQ:ACIU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACIU at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- AC Immune Initiates Phase 1 Clinical Trial for Novel NLRP3 Inhibitor ACI-19764 Targeting Neurodegenerative Diseases
- AC Immune's Partner Janssen Temporarily Pauses Enrollment in Phase 2b Alzheimer's Trial
Financial Snapshot
Insider Transactions
ACIU files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.